Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02784496 · ClinicalTrials.gov registry record · Phase 2
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02784496: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02784496 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02784496, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase II trial studies the long-term side effects of ruxolitinib in treating patients with myelofibrosis. Collecting data about the long-term safety and tolerability of ruxolitinib may better help future patients with myelofibrosis.
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Ruxolitinib
- OTHER Long-term Follow-up
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-09-29 |
| Est. Completion | 2024-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02784496
The ClinicalTrials.gov registry entry for NCT02784496 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02784496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02784496 about?
NCT02784496 is a clinical study titled "Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis". This phase II trial studies the long-term side effects of ruxolitinib in treating patients with myelofibrosis. Collecting data about the long-term safety and tolerability of ruxolitinib may better help future patients with myelofibrosis.
What is the current status of trial NCT02784496?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-09-29. Estimated completion is 2024-01-23.
What interventions are being tested in trial NCT02784496?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Ruxolitinib (DRUG), Long-term Follow-up (OTHER).
Who is sponsoring clinical trial NCT02784496?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.